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Background: Current cost estimates for atrial fibrillation (AF) in the US vary depending on the analysis method/population used. This retrospective 
study aimed to provide an up-to-date, comprehensive estimate of the national cost of treating AF patients (pts) compared with matched pts without AF. 
Methods: Pts aged ≥20 yrs with ≥1 inpatient or ≥2 outpatient AF diagnoses in 2005 (first diagnosis = index), and ≥12 months enrolment pre and 
post index, were identified from the MarketScan® databases from Thomson Reuters. AF pts were propensity score matched to comparison pts without 
AF (1:1) based on age, sex, region, payer and cardiovascular (CV) comorbidities. Medical costs (2008 US$), including AF costs (for antiarrhythmics or 
claims with a primary AF diagnosis), other CV costs (claims with other primary CV diagnoses) and non-CV costs (all other claims), were examined over 
1 yr post index. National incremental costs in AF pts were estimated based on age/sex-specific AF prevalence projections 2010. 
Results: In total, 89 066 AF pts (mean age 71 yrs) were matched to comparison pts without AF. Over 1 yr, 38% of AF pts were hospitalized and 2% 
died during hospitalization. Of comparison pts, 18% were hospitalized and 0.1% died during hospitalization. For AF vs comparison pts, mean annual 
inpatient costs per pt were $7841 vs 2622 (incremental cost $5218), outpatient costs $9225 vs 5629 (incremental cost $3596) and total drug 
costs $3605 vs 3714 (incremental cost -$109) (all P <0.001). AF pts had total incremental costs vs comparison pts of $8705 per pt, comprising AF 
costs of $1945, other CV costs $3211 and non-CV costs $3550 (all P <0.001). When applied to national AF prevalence data, incremental costs in AF 
pts were $26.0 billion (AF costs $6.0 billion, other CV $9.9 billion, non-CV $10.1 billion). 
Conclusion: US medical costs in 2010 are likely to be substantially higher in AF pts than similar pts without AF due both to care primarily for AF/CV 
disease and care primarily for non-CV conditions. Excess non-CV costs in AF pts may be due to treatment of AF/CV disease as a secondary diagnosis 
or greater risk of non-CV disorders in AF pts. Improved AF management strategies are needed to reduce the national cost burden of this condition.
